Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma—Protocol of the Immuno-MESODEC study

Source
PLoS ONE - ISSN 1932-6203-19:7 (2024) p. 1-15
Author(s)

Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma : protocol of a monocentric phase I/II clinical trial in Belgium

Source
BMJ open - ISSN 2044-6055-14:3 (2024) p. 1-10
Author(s)